Truist Raises Centene Target to $49, Expects 40% EPS Growth in 2026
Truist lifted Centene’s price target to $49 from $47 and maintained a Buy rating after management cited meaningful margin opportunities across all segments. CEO Sarah London reported Q4 2025 adjusted loss per share of ($1.19) and full-year EPS of $2.08, forecasting 2026 adjusted EPS above $3 for over 40% growth.
1. Truist Raises Price Target
Following positive management discussions, Truist raised Centene’s price target to $49 from $47 and maintained a Buy rating. The firm highlighted meaningful margin opportunities across Medicaid, Marketplace and Medicare segments and cited ongoing initiatives as drivers of steady performance improvement.
2. Q4 and Full-Year 2025 Results
In Q4 2025, Centene reported an adjusted loss per share of ($1.19) and delivered full-year 2025 adjusted EPS of $2.08, slightly above prior guidance. Profitability improved in Medicaid while Marketplace and Medicare results met or slightly exceeded expectations, supported by disciplined execution.
3. Strong 2026 Outlook
The company projects adjusted EPS above $3 for full-year 2026, implying more than 40% year-over-year growth. This outlook assumes stable Medicaid margins, meaningful margin recovery in Marketplace and progress toward breakeven in the Medicare Advantage business.